Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc. (RXRX)
Filing Type: Form 8-K (Current Report)
Date of Report: November 19, 2024 (Event Date: November 20, 2024)
Primary Event: Completion of the acquisition of Exscientia plc (Exscientia) via a Scheme of Arrangement. Exscientia is now a wholly-owned subsidiary of Recursion.
Key Financial Metrics and Transaction Details
Transaction Consideration:
- Exchange Ratio: 0.7729 shares of Recursion Class A Common Stock for each Exscientia Ordinary Share (or ADS).
- Shares Issued: 102,138,419 shares of Recursion Class A Common Stock issued to Exscientia shareholders.
- Delisting: Exscientia ADSs (symbol: EXAI) ceased trading on Nasdaq and will be delisted.
Financial Statements:
- Exscientia's audited financial statements for years ended Dec 31, 2023, and 2022, and unaudited statements for periods ended Sept 30, 2024, are incorporated by reference (Exhibits 99.3 and 99.4).
- Pro Forma Data: Not included in this filing; expected to be filed via amendment within 71 days.
Equity Incentives:
- Adoption of the 2024 Inducement Equity Incentive Plan, reserving 17,500,000 shares for new hires.
- Exscientia equity awards (options and RSUs) were converted to Recursion equivalents or cashed out based on vesting status and the Exchange Ratio.
Material Changes and Executive Leadership
Board of Directors:
- Board size increased from 7 to 8 members.
- New Director: Franziska Michor, Ph.D., appointed as a Class II Director (term through 2026 Annual Meeting).
Executive Officer Changes (Effective Nov 20, 2024):
- Christopher Gibson, Ph.D.: Appointed as President (in addition to CEO).
- Ben Taylor: Appointed as Chief Financial Officer (CFO) and President of Recursion UK. Previously CFO of Exscientia.
- Michael Secora: Transitioned from CFO to Executive Advisor (through Dec 31, 2024). Entitled to severance including a $356,250 lump sum and bonus payments totaling $190,000 (cash and RSUs).
- Tina Marriott: Transitioned from President/COO to Executive Advisor (through Aug 31, 2025). Entitled to continued salary, bonus, and potential severance if terminated prior to Aug 31, 2025.
- David Hallet: Appointed Chief Scientific Officer (formerly Interim CEO of Exscientia).
- Kristen Rushton: Promoted to Chief Operating Officer.
- Matthew Kinn: Promoted to Chief Business Officer.
- Lina Nilsson: Promoted to Senior Vice President, Head of Platform.
Outlook, Risks, and Contingencies
Management Commentary:
- The transaction was sanctioned by the High Court of Justice of England and Wales on November 19, 2024, and became effective upon delivery to the Registrar on November 20, 2024.
- Performance-vesting conditions on Exscientia equity awards were deemed achieved at the greater of target level or actual achievement as of the preceding quarter-end.
Risks and Contingencies:
- Integration Risk: Significant leadership turnover and integration of Exscientia's operations and technology platform.
- Financial Impact: Pro forma financial information is pending; immediate impact on Recursion's capitalization includes the issuance of ~102 million shares.
- Regulatory: The transaction relied on a UK Scheme of Arrangement; future regulatory approvals for combined pipeline assets remain subject to standard processes.
Investor Verification Checklist
- Pro Forma Financials: Verify the upcoming amendment to this 8-K for pro forma financial data to assess the combined entity's liquidity and burn rate.
- Share Count Impact: Confirm the exact post-transaction share count and dilution impact of the 102,138,419 shares issued.
- Executive Retention: Monitor the transition periods for Michael Secora and Tina Marriott to ensure smooth handover of financial and operational duties.
- Equity Plan Details: Review the 2024 Inducement Equity Incentive Plan (Exhibit 99.1) for terms regarding the 17.5 million reserved shares.
- Exscientia Financials: Review Exhibits 99.3 and 99.4 for Exscientia's standalone financial health prior to consolidation.